SV BR 1 GM cancer vaccine - BriaCell Therapeutics

Drug Profile

SV BR 1 GM cancer vaccine - BriaCell Therapeutics

Alternative Names: Allogeneic GM CSF secreting breast cancer vaccine - BriaCell Therapeutics; BriaVax; GM CSF gene-transfected breast cancer vaccine - BriaCell Therapeutics; SV-BR-1-GM-vaccine-BriaCell-Therapeutics; SV-BR1-GM-breast-cancer-vaccine-BriaCell-Therapeutics

Latest Information Update: 03 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Wiseman Research Initiatives LLC
  • Developer BriaCell Therapeutics Corp; Saint Vincent Catholic Medical Centers; Wiseman Research Initiatives LLC
  • Class Cancer vaccines; Gene therapies; Immunotherapies
  • Mechanism of Action Gene transference; Granulocyte-macrophage colony-stimulating factor expression stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Breast cancer
  • Phase I Ovarian cancer

Most Recent Events

  • 06 Nov 2017 BriaCell Therapeutics and Cancer Insight plan a phase I/II trial for Breast cancer (Combination therapy, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in USA in first quarter of 2018 (NCT03328026)
  • 30 Oct 2017 The US FDA approves the roll-over combination study for SV BR 1 GM cancer vaccine in Breast cancer
  • 14 Sep 2017 BriaCell enters into a research collaboration with University of Zurich to evaluate BriaVax in combination with an immune stimulator
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top